UCB SA (OTCMKTS:UCBJY) Sees Significant Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 14,956 shares, an increase of 668.9% from the August 15th total of 1,945 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 67,990 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Zacks Research raised shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Finally, Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy”.

UCB Price Performance

Shares of OTCMKTS UCBJY opened at $119.35 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The firm has a 50-day moving average of $130.83 and a 200 day moving average of $141.17. UCB has a 1 year low of $114.53 and a 1 year high of $168.76.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.